Remove Compounding Remove Dosage Remove Packaging Remove Vaccines
article thumbnail

Prefilled syringes and vaccines: Optimising parenteral packaging for the next pandemic

Pharmaceutical Technology

When it comes to vaccines and other high-value biologics, it is essential that effective formulations go hand in hand with safe delivery. An example is the ability of a patient suffering from venous thrombosis to perform their own injections of heparin – an anticoagulant often packaged in a prefilled syringe.

article thumbnail

Top 5 Reasons to Attend the 2023 ISPE Aseptic Conference

ISPE

I presented on planning and executing and designing fill lines, RABS, Isolators, and transfers – along with the differences between processing potent compounds versus non- potent compounds. When I started attending and speaking at the ISPE Aseptic Conference in the 2000s, I came to grow and learn. Learn More & Register.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Contamination Trends & Proposed Solutions

ISPE

The cases covered the same types of contaminants and impurities noted in Table 1: microbial contaminants, process-related im-purities, metal contaminants, packaging-related contaminants, drug cross-contamination, and an “unknown” category encompassing other contaminants associated with the manufacturing process, including those from cell culturing.

article thumbnail

Considerations for a Decentralized Manufacturing Paradigm

ISPE

4 , 5 Additionally, reducing shipping limitations—such as packaging, storage, and transportation durations—helps speed up patient access in certain instances while ensuring there is no negative impact to the product’s critical quality attributes (CQAs). These new operating models can help enable and accelerate the efforts of Pharma 4.0™

article thumbnail

Regulatory Landscape for Raw Materials: CMC Considerations

ISPE

With shortages, regulatory complexity is compounded due to differences in submission and data requirements from various regulatory agencies. In this article, the term “raw material” refers to a material used in the manufacturing and packaging of a drug substance (DS) or a drug product (DP). Burke, PhD. 1 September 2022.